BILLERICA, Mass. / Nov 12, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:
Stifel 2024 Healthcare Conference in New York City
Monday, November 18, 2024, at 8:35 a.m. Eastern Time
Wolfe Research 2024 Healthcare Conference in New York City
Tuesday, November 19, 2024, at 4:10 p.m. Eastern Time
Nasdaq 51st Investor Conference in London, UK
Tuesday, December 10, 2024, at 6:30 a.m. Eastern Time
Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
| Last Trade: | US$36.28 |
| Daily Change: | -1.46 -3.87 |
| Daily Volume: | 3,434,032 |
| Market Cap: | US$5.500B |
April 17, 2025 April 02, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
